Equity Briefing: Exec hints at doubling revenues and a possible spin-off dividend for NEPT investors

Wael Massrieh, the VP of Scientific affairs for Neptune Technologies and Bioresources (NASDAQ: NEPT), in a videotaped interview on Wednesday hinted that his firm will see a substantial increase in revenues due to their plant expansion roll-out. "Our previous capacity was 150 metric tons before we started the expansion. The capacity is actually going to go up to 300 metric tons by the end of the year...

Wael Massrieh, the VP of Scientific affairs for Neptune Technologies and Bioresources (NASDAQ: NEPT), in a videotaped interview on Wednesday hinted that his firm will see a substantial increase in revenues due to their plant expansion roll-out.

"Our previous capacity was 150 metric tons before we started the expansion. The capacity is actually going to go up to 300 metric tons by the end of the year. So that actually means that we're going to end up doubling our revenues by the end of the year if the whole capacity is capitalized on.

Neptune has considerable ownership stakes in the subsidiary Acasti Pharma (TSX:APO). That intriguing biotech spin-offs seeking to develop and exploit pharmaceutical applications for marine omega-3 phospholipid bioactive ingredients in huge multi-billion dollar markets, each with vast unmet needs.

Massrieh also hinted that Neptune shareholders may soon be given an opportunity to own shares of a new biotech spin-off shortly.

"This company is actually called NeuroBioPharm and it will be spun off in the next couple of months," explained  and it's going to follow a very similar strategy to how Acasti was successfully spun out. The idea there is basically is that the Neptune shareholders will actually have access to ownership of NeuroBioPharm before it actually even starts trading publicly."

Volume in the stock was trading at levels much higher than average, on Wednesday with official announcements set to follow.

Interview Source: http://bit.ly/IJYcSa

Copyright Thomson Reuters


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: %s via Thomson Reuters ONE


[HUG#1606087]